These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

131 related articles for article (PubMed ID: 32472122)

  • 41. Human leukemic cell lines synthesize hyaluronan to avoid senescence and resist chemotherapy.
    Lompardía SL; Papademetrio DL; Mascaró M; Álvarez EM; Hajos SE
    Glycobiology; 2013 Dec; 23(12):1463-76. PubMed ID: 24013961
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Nuclear factor I A promotes temozolomide resistance in glioblastoma via activation of nuclear factor κB pathway.
    Yu X; Wang M; Zuo J; Wahafu A; Mao P; Li R; Wu W; Xie W; Wang J
    Life Sci; 2019 Nov; 236():116917. PubMed ID: 31614149
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Selective Estrogen Receptor β Agonist LY500307 as a Novel Therapeutic Agent for Glioblastoma.
    Sareddy GR; Li X; Liu J; Viswanadhapalli S; Garcia L; Gruslova A; Cavazos D; Garcia M; Strom AM; Gustafsson JA; Tekmal RR; Brenner A; Vadlamudi RK
    Sci Rep; 2016 Apr; 6():24185. PubMed ID: 27126081
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Exosomal transfer of miR‑25‑3p promotes the proliferation and temozolomide resistance of glioblastoma cells by targeting FBXW7.
    Wang J; Li T; Wang B
    Int J Oncol; 2021 Aug; 59(2):. PubMed ID: 34278448
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Tetra-O-methyl nordihydroguaiaretic acid, an inhibitor of Sp1-mediated survivin transcription, induces apoptosis and acts synergistically with chemo-radiotherapy in glioblastoma cells.
    Castro-Gamero AM; Borges KS; Moreno DA; Suazo VK; Fujinami MM; de Paula Gomes Queiroz R; de Oliveira HF; Carlotti CG; Scrideli CA; Tone LG
    Invest New Drugs; 2013 Aug; 31(4):858-70. PubMed ID: 23299390
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Tumor-suppressive functions of 4-MU on breast cancer cells of different ER status: Regulation of hyaluronan/HAS2/CD44 and specific matrix effectors.
    Karalis TT; Heldin P; Vynios DH; Neill T; Buraschi S; Iozzo RV; Karamanos NK; Skandalis SS
    Matrix Biol; 2019 May; 78-79():118-138. PubMed ID: 29673760
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Intranasal Delivery of Temozolomide-Conjugated Gold Nanoparticles Functionalized with Anti-EphA3 for Glioblastoma Targeting.
    Wang L; Tang S; Yu Y; Lv Y; Wang A; Yan X; Li N; Sha C; Sun K; Li Y
    Mol Pharm; 2021 Mar; 18(3):915-927. PubMed ID: 33417456
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Hyaluronic acid family in bladder cancer: potential prognostic biomarkers and therapeutic targets.
    Morera DS; Hennig MS; Talukder A; Lokeshwar SD; Wang J; Garcia-Roig M; Ortiz N; Yates TJ; Lopez LE; Kallifatidis G; Kramer MW; Jordan AR; Merseburger AS; Manoharan M; Soloway MS; Terris MK; Lokeshwar VB
    Br J Cancer; 2017 Nov; 117(10):1507-1517. PubMed ID: 28972965
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Targeting the ABC transporter ABCB5 sensitizes glioblastoma to temozolomide-induced apoptosis through a cell-cycle checkpoint regulation mechanism.
    Lee CAA; Banerjee P; Wilson BJ; Wu S; Guo Q; Berg G; Karpova S; Mishra A; Lian JW; Tran J; Emmerich M; Murphy GF; Frank MH; Frank NY
    J Biol Chem; 2020 May; 295(22):7774-7788. PubMed ID: 32317280
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Cordycepin Augments the Chemosensitivity of Human Glioma Cells to Temozolomide by Activating AMPK and Inhibiting the AKT Signaling Pathway.
    Bi Y; Li H; Yi D; Sun Y; Bai Y; Zhong S; Song Y; Zhao G; Chen Y
    Mol Pharm; 2018 Nov; 15(11):4912-4925. PubMed ID: 30336060
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Ellagic acid inhibits human glioblastoma growth in vitro and in vivo.
    Wang D; Chen Q; Tan Y; Liu B; Liu C
    Oncol Rep; 2017 Feb; 37(2):1084-1092. PubMed ID: 28035411
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Afatinib and Temozolomide combination inhibits tumorigenesis by targeting EGFRvIII-cMet signaling in glioblastoma cells.
    Vengoji R; Macha MA; Nimmakayala RK; Rachagani S; Siddiqui JA; Mallya K; Gorantla S; Jain M; Ponnusamy MP; Batra SK; Shonka N
    J Exp Clin Cancer Res; 2019 Jun; 38(1):266. PubMed ID: 31215502
    [TBL] [Abstract][Full Text] [Related]  

  • 53. 4-Methylumbelliferone Decreases the Hyaluronan-rich Extracellular Matrix and Increases the Effectiveness of 5-Fluorouracil.
    Yoshida E; Kudo D; Nagase H; Suto A; Shimoda H; Suto S; Kakizaki I; Endo M; Hakamada K
    Anticancer Res; 2018 Oct; 38(10):5799-5804. PubMed ID: 30275202
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Enhanced Anti-Tumor Activity in Mice with Temozolomide-Resistant Human Glioblastoma Cell Line-Derived Xenograft Using SN-38-Incorporated Polymeric Microparticle.
    Yang TC; Liu SJ; Lo WL; Chen SM; Tang YL; Tseng YY
    Int J Mol Sci; 2021 May; 22(11):. PubMed ID: 34074038
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Dissecting the role of novel EZH2 inhibitors in primary glioblastoma cell cultures: effects on proliferation, epithelial-mesenchymal transition, migration, and on the pro-inflammatory phenotype.
    Stazi G; Taglieri L; Nicolai A; Romanelli A; Fioravanti R; Morrone S; Sabatino M; Ragno R; Taurone S; Nebbioso M; Carletti R; Artico M; Valente S; Scarpa S; Mai A
    Clin Epigenetics; 2019 Dec; 11(1):173. PubMed ID: 31791385
    [TBL] [Abstract][Full Text] [Related]  

  • 56. TROY (TNFRSF19) promotes glioblastoma survival signaling and therapeutic resistance.
    Loftus JC; Dhruv H; Tuncali S; Kloss J; Yang Z; Schumacher CA; Cao B; Williams BO; Eschbacher JM; Ross JT; Tran NL
    Mol Cancer Res; 2013 Aug; 11(8):865-74. PubMed ID: 23699535
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Exosomal transfer of long non-coding RNA SBF2-AS1 enhances chemoresistance to temozolomide in glioblastoma.
    Zhang Z; Yin J; Lu C; Wei Y; Zeng A; You Y
    J Exp Clin Cancer Res; 2019 Apr; 38(1):166. PubMed ID: 30992025
    [TBL] [Abstract][Full Text] [Related]  

  • 58. The PI3K inhibitor GDC-0941 enhances radiosensitization and reduces chemoresistance to temozolomide in GBM cell lines.
    Shi F; Guo H; Zhang R; Liu H; Wu L; Wu Q; Liu J; Liu T; Zhang Q
    Neuroscience; 2017 Mar; 346():298-308. PubMed ID: 28147244
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Hyaluronan synthesis inhibition impairs antigen presentation and delays transplantation rejection.
    Marshall PL; Nagy N; Kaber G; Barlow GL; Ramesh A; Xie BJ; Linde MH; Haddock NL; Lester CA; Tran QL; de Vries CR; Hargil A; Malkovskiy AV; Gurevich I; Martinez HA; Kuipers HF; Yadava K; Zhang X; Evanko SP; Gebe JA; Wang X; Vernon RB; de la Motte C; Wight TN; Engleman EG; Krams SM; Meyer EH; Bollyky PL
    Matrix Biol; 2021 Feb; 96():69-86. PubMed ID: 33290836
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Encapsulation of Temozolomide in a Calixarene Nanocapsule Improves Its Stability and Enhances Its Therapeutic Efficacy against Glioblastoma.
    Renziehausen A; Tsiailanis AD; Perryman R; Stylos EK; Chatzigiannis C; O'Neill K; Crook T; Tzakos AG; Syed N
    Mol Cancer Ther; 2019 Sep; 18(9):1497-1505. PubMed ID: 31213505
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.